National Institutes of Health, a Component of the US Dept. of Health & Human Services

Lentigen Technology, Inc.

Biomed Valley Discoveries, Inc.

The Children's Hospital of Philadelphia

The Henry M. Jackson Foundation for the Advancement of Military Medicine Inc.

Other

The United States of America As Represented by the Department of Health

Zhongyu Zhu

Dimiter Stanchev Dimitrov

Rimas J Orentas

Dina Schneider

Boro Dropulic

Saurabh Saha

Xiaoyan Michelle Zhang

Brad St Croix

Enrique Zudaire

Bradley St Croix

Dean Welsch

Gary DeCrescenzo

Crystal L Mackall

Jeffrey Baron

Crystal Sao Fong Cheung

Julian Chun Kin Lui

Christopher C Broder

Javed Khan

Sivasubramanian Baskar

John M Maris

Steven Seaman

Tai Chi Cheuk

Leah Marie Alabanza

Bang Khoa Vu

Qi Zhao

Yang Feng

Terry J Fry

Joost J Oppenheim

Gary A Decrescenzo

De Yang

Boopathy Ramakrishnan

Pradman K Qasba

Dontcho V Jelev

Florian Tomszak

Rafijul Bari

Kristopher R Bosse

Nayanendu Saha

Dorothea Robev

Thomas Edgeworth White

Sneha Ramakrishna

Dimitar Nikolov

Xin Chen

Robyn Tovah Sussman

Diviter S Dimitrov

Monoclonal antibodies selected from immunized mice, immunized rabbits and a human scFv library that specifically bind fibroblast growth factor receptor 4 (FGFR4) are described. Chimeric antigen receptors, antibody-drug conjugates, immunoconjugates, bispecific antibodies and immunoliposomes comprising the disclosed FGFR4-specific antibodies are also described. The antibody compositions can be used to diagnose or treat a FGFR4-positive cancer, such as rhabdomyosarcoma, lung cancer, liver cancer, breast cancer, pancreatic cancer or prostate cancer.

Monoclonal antibodies specific for fibroblast growth factor receptor 4 (FGFR4) and methods of their use

Chimeric antigen receptors containing BCMA antigen binding domains are disclosed. Nucleic acids, recombinant expression vectors, host cells, antigen binding fragments, and pharmaceutical compositions, relating to the chimeric antigen receptors are also disclosed. Methods of treating or preventing cancer in a subject, and methods of making chimeric antigen receptor T cells are also disclosed.

Compositions and methods for treating cancer with anti-BCMA immunotherapy

Chimeric antigen receptors containing CD38 antigen binding domains are disclosed. Nucleic acids, recombinant expression vectors, host cells, antigen binding fragments, and pharmaceutical compositions, relating to the chimeric antigen receptors are also disclosed. Methods of treating or preventing cancer in a subject, and methods of making chimeric antigen receptor T cells are also disclosed.

Compositions and methods for treating cancer with anti-CD38 immunotherapy

The present invention provides various ADAM17 binding molecules (including antibodies and fragments thereof), compositions comprising such ADAM17 binding molecules, and methods of using such ADAM17 binding molecules and compositions, for example in inhibiting binding of ADAM17 to ADAM17 substrates (such as ErbB ligands), in inhibiting the proliferation of cancer cells, and in treating cancer.

ADAM17 binding molecules and uses thereof

Chimeric antigen receptors containing CD123 antigen binding domains are disclosed. Nucleic acids, recombinant expression vectors, host cells, antigen binding fragments, and pharmaceutical compositions, relating to the chimeric antigen receptors are also disclosed. Methods of treating or preventing cancer in a subject, and methods of making chimeric antigen receptor T cells are also disclosed.

Compositions and methods for treating cancer with anti-CD123 immunotherapy

Chimeric antigen receptors containing mesothelin antigen binding domains are disclosed. Nucleic acids, recombinant expression vectors, host cells, antigen binding fragments, and pharmaceutical compositions, relating to the chimeric antigen receptors are also disclosed. Methods of treating or preventing cancer in a subject, and methods of making chimeric antigen receptor T cells are also disclosed.

Compositions and methods for treating cancer with anti-mesothelin immunotherapy

An affinity matured anti-CD22 human monoclonal antibody exhibiting significantly higher affinity (less than 50 pM) compared to the parental antibody (affinity of about 2 nM) is described. The anti-CD22 variant antibody or a fragment thereof, such as a single-chain variable fragment (scFv), can be used as the antigen-binding portion of chimeric antigen receptors (CARs), antibody-drug conjugates (ADCs), immunotoxins or multi-specific antibodies for the treatment of B-cell malignancies.

Affinity matured CD22-specific monoclonal antibody and uses thereof

Chimeric antigen receptors (CARs) containing CD22 antigen binding domains are disclosed. Nucleic acids, recombinant expression vectors, host cells, antigen binding fragments, and pharmaceutical compositions, relating to the CARs are also disclosed. Methods of treating or preventing cancer in a subject, and methods of making CAR T cells are also disclosed.

Compositions and methods for treating cancer with anti-CD22 immunotherapy

Polypeptides and proteins that specifically bind to and immunologically recognize CD276 are disclosed. Chimeric antigen receptors (CARs), anti-CD276 binding moieties, nucleic acids, recombinant expression vectors, host cells, populations of cells, pharmaceutical compositions, and conjugates relating to the polypeptides and proteins are also disclosed. Methods of detecting the presence of (a) cancer or (b) tumor vasculature in a mammal and methods of (a) treating or preventing cancer or (b) reducing tumor vasculature in a mammal are also disclosed.

Anti-CD276 antibodies (B7H3)

The present disclosure is directed to antibodies binding to Glypican 2 and methods of using such antibodies to treat cancers that express or overexpress the Glypican 2 antigen.

Glypican 2 as a cancer marker and therapeutic target

Chimeric antigen receptors containing human CD19 antigen binding domains are disclosed. Nucleic acids, recombinant expression vectors, host cells, antigen binding fragments, and pharmaceutical compositions, relating to the chimeric antigen receptors are also disclosed. Methods of treating or preventing cancer in a subject, and methods of making chimeric antigen receptor T cells are also disclosed.

Compositions and methods for treating cancer with anti-CD19 immunotherapy

Monoclonal antibodies and antibody fragments that specifically bind to matrilin-3, conjugates including these molecules, and nucleic acid molecules encoding the antibodies, antigen binding fragments and conjugates, are disclosed. Also disclosed are compositions including the disclosed antibodies, antigen binding fragments, conjugates, and nucleic acid molecules. Methods of treating or inhibiting a cartilage disorder in a subject, as well as methods of increasing chondrogenesis in cartilage tissue are further provided. The methods can be used, for example, for treating or inhibiting a growth plate disorder in a subject, such as a skeletal dysplasia or short stature.

Monoclonal antibodies that specifically bind to matrilin 3 and their use

Polypeptides and proteins that specifically bind to and immunologically recognize CD276 are disclosed. Chimeric antigen receptors (CARs), anti-CD276 binding moieties, nucleic acids, recombinant expression vectors, host cells, populations of cells, and pharmaceutical compositions relating to the polypeptides and proteins are also disclosed. Methods of detecting the presence of cancer in a mammal and methods of treating or preventing cancer in a mammal are also disclosed.

Anti-CD276 polypeptides, proteins, and chimeric antigen receptors

Chimeric antigen receptors containing CD33 antigen binding domains are disclosed. Nucleic acids, recombinant expression vectors, host cells, antigen binding fragments, and pharmaceutical compositions, relating to the chimeric antigen receptors are also disclosed. Methods of treating or preventing cancer in a subject, and methods of making chimeric antigen receptor T cells are also disclosed.

Compositions and methods for treating cancer with anti-CD33 immunotherapy

Growing community of inventors

Frederick, MD, United States of America

Zhongyu Zhu